Hematologic Malignancies Market Share 2022 | Industry Size, Growth, Trends And Forecast 2027
According to the latest report by IMARC Group, titled “Hematologic Malignancies Market: Global Industry Trends, Size, Growth, Opportunity and Forecast 2022-2027″,The global hematologic malignancies market size reached US$ 50.1 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 91.2 Billion by 2027, exhibiting a growth rate (CAGR) of 10.6% during 2022-2027.
Industry Definition and Application:
Hematologic malignancies or hematological diseases aare cancers impacting lymph nodes, bone marrow, and blood. These cells consist of platelets, red blood cells (RBCs) to carry oxygen, wound clotting, and white blood cells (WBCs) for immune protection, originating from hematopoietic stem and progenitor cells in the bone marrow. They can be diagnosed using immunophenotyping, flow cytometry, microscopy, cytogenetics, fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), and gene expression profiling. They are treated using several drugs, such as histone deacetylase inhibitors, antitumor antibiotics, and Janus kinase (JAK) inhibitors. Nowadays, hematologic malignancies treatment solutions are widely adopted across hospitals, diagnostics centers, and research centers across the globe.
Global Hematologic Malignancies Market Trends:
The market is primarily driven by the growing incidences of blood cancers and the development of innovative treatments. In addition, the increasing prevalence of acute myeloid leukemia (AML) among the geriatric population is contributing to market growth. Moreover, the introduction of numerous novel therapies and multiple label expansions of premium-priced agents, including brexucabtagene autoleuce, and CAR T-cell therapies, represents another major growth-inducing factor. Besides this, with the advancement in immunohistochemistry (IHC), hematologic malignancies can be diagnosed accurately by exposing tissue samples to numerous antibodies directed against antigens and cell molecules, providing a positive thrust to the market growth. Furthermore, the extensive research and development (R&D) activities to develop advanced drugs for patients with hematologic malignancies, and the growing awareness of early diagnosis and improved diagnostic modalities are creating a favorable market outlook.
Request Free Sample Report: https://www.imarcgroup.com/hematologic-malignancies-market/requestsample
Global Hematologic Malignancies Market 2022-2027 Analysis and Segmentation:
Competitive Landscape:
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
- AbbVie Inc.
- AstraZeneca plc
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline plc
- Johnson & Johnson
- Merck & Co. Inc
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited.
The report has segmented the market on the based on region, type, therapy and end user.
Breakup by Type:
- Leukemia
- Lymphoma
- Multiple Myeloma
- Others
Breakup by Therapy:
- Chemotherapy
- Radiotherapy
- Immunotherapy
- Stem Cell Transplantation
- Others
Breakup by End User:
- Hospitals
- Diagnostics Centers
- Research Centers
- Others
Breakup by Region:
- North America: (United States, Canada)
- Asia Pacific: (China, Japan,India, South Korea, Australia, Indonesia, Others)
- Europe: (Germany, France,United Kingdom, Italy, Spain, Russia, Others)
- Latin America: (Brazil, Mexico, Others)
- Middle East and Africa
Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/request?type=report&id=4133&flag=C
Key highlights of the report:
Market Performance (2016-2021)
Market Outlook (2022- 2027)
Porter’s Five Forces Analysis
Market Drivers and Success Factors
SWOT Analysis
Value Chain
Comprehensive Mapping of the Competitive Landscape
Note: We are in the process of updating our reports. If you want to receive the latest research data covering the time period from 2023 to 2028, along with industry trends, market size, and competitive analysis, click on the request sample report. The team would be able to deliver the latest version of the report in a quick turnaround time.
If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
Related Reports By IMARC Group
Autoimmune Disease Diagnosis Market Size
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact Us:
IMARC Group
Email: sales@imarcgroup.com
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Address: 134 N 4th St. Brooklyn, NY 11249, USA
Website: https://www.imarcgroup.com/
Follow us on Twitter: @imarcglobal
Linkedin: https://www.linkedin.com/company/imarc-group
